Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company is set to start a phase 2/3 trial this month.
Some time ago Opdivo beat Advetris in an NCI trial, and now Bristol files.
The group will start a pivotal trial of samuraciclib following promising second-line results.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Global phase 2 data in TNBC look similar to earlier results in China.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
